A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
Case: A 62-Year-Old Woman With MetastaticBRAFV600E-Mutated NSCLC
Initial Presentation
Clinical Workup
Treatment and Follow-Up
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More